VBI Vaccines Inc.
NASDAQ:VBIV
0.07 (USD) • At close August 7, 2024
Overzicht | Financiële gegevens
| Bedrijfsnaam | VBI Vaccines Inc. |
| Symbool | VBIV |
| Munteenheid | USD |
| Prijs | 0.065 |
| Beurswaarde | 1,872,954 |
| Dividendpercentage | 0% |
| 52-weken bereik | 0.057 - 1.35 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Jeffery R. Baxter FCMA |
| Website | https://www.vbivaccines.com |
An error occurred while fetching data.
Over VBI Vaccines Inc.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









